Kornimate/medical-research-clean huggingface dataset:
bariatric surgery and exercise interventions: effects on muscle

Conditions: Bariatric Surgery Candidate; Obesity

Summary: the purpose of this project is to assess the effects of bariatric surgery on muscle structure and function as well as investigating the feasibility of undertaking an exercise intervention post-surgery.

a single-centre feasibility research programme based at the royal derby hospital centre of the university of nottingham. this is an exploratory and feasibility study. muscle structure and function of 12 patients will be assessed before bariatric surgery and at 6 weeks, and then 10 weeks, after surgery. after 6 weeks, participants will be randomised into two groups. group 1 will undergo a 4 week resistance exercise training (ret). group 2 will undergo standard care procedure. the total duration of programme we are aiming for is 13-14 weeks prior to bariatric surgery and exercise intervention for 4 weeks after bariatric surgery.

Eligibility criteria:
inclusion criteria: * obese adults (bmi greater than or equal to 35 kg/m2) * age range 18-70 years old * scheduled for rygb surgery or sleeve gastrectomy surgery. * ability to give informed consent exclusion criteria: * patients who are not fit or not suitable for rygb or sleeve gastrectomy as per tier 4 bariatric surgery mdt. * for those high-risk patients who are fast tracked to surgery, we will exclude patients with a nyha \>3 or 4 heart failure status and those with end stage renal failure. * bmi greater than or equal to 60

Keywords: resistance exercise therapy
a pilot randomized controlled trial: cointegrate

Conditions: Neurocognitive Disorders; Cognitive Dysfunction; Traumatic Brain Injury; Multiple Sclerosis; Mild Cognitive Impairment

Summary: the purpose of this study is to examine the feasibility of comprehensive multimodal individually tailored cognitive behavioral therapy (cbt), cognitive rehabilitation therapy (crt), and modifiable lifestyle sessions. the study team hypothesizes that combining evidence-based cognitive and affective therapies with lifestyle modifications is feasible and will improve the community integration (ci) and quality of life (qol) in patients with a neurocognitive disorder compared to usual care.


Eligibility criteria:
inclusion criteria: * diagnosed with one of the following: mild trauma brain injury (tbi), multiple sclerosis (ms), long covid, or mild cognitive impairment (mci) * mci patients age older than 50 years old, all other diagnosis 21-65 years old and are receiving care through the michigan medicine network * participants that can provide consent or legally authorized representative who can provide consent on their behalf * cognitive impairment ≥ 1.0 standard deviation below the test score normed for age and education in at least 2 cognitive domains (verbal learning and memory, processing speed, or visuospatial memory) exclusion criteria: * tbi participants symptomatic at rest (headache, dizziness, nausea, or vertigo) will be referred to primary care physician (pcp) * history of tbi (except for participants with tbi) * ms participants with recent relapse (1 month prior to enrollment) or on intravenous or oral steroids * mci participants with disease duration greater than 1 year * patients with other neurosensory or neurodegenerative diseases * diagnosed with covid-19 (except for long covid group) * psychiatric disorders other than mild to moderate anxiety and depression * patients with severe depression or suicidal (ideation or plan) will be instructed to seek mental health, provided with resources and referred to patient's primary care provider * diagnosed sleep disorders * visual or auditory impairment, * current or history of alcohol or substance abuse/dependence * cognitive impairment less than 1.0 standard deviation below the test score normed for age and education in at least 2 cognitive domains (verbal learning and memory, processing speed, or visuospatial memory) * cognitive impairment greater or equal to 1.0 standard deviation below the test score normed for age and education in 1 cognitive domain (verbal learning and memory, processing speed, or visuospatial memory) * currently receiving crt, cbt or occupational therapy (ot) or another type of psychological therapy

Keywords: affective dysfunction cognitive behavioral therapy modifiable lifestyle factors cognitive rehabilitation therapy long covid (coronavirus disease)
non-adherence to pain medication increases risk of postoperative frozen shoulder

Conditions: Frozen Shoulder; Depression

Summary: background: postoperative frozen-shoulder (fs) or adhesive capsulitis is a relatively frequent complication (5-20%), even after simple arthroscopic shoulder surgeries. the pathophysiology is still unclear, but psychological factors may play a pivotal role. from clinical experience, the investigators hypothesized that participants, who are reluctant to take medications, particularly "pain-killers", have an increased incidence of postoperative fs. the investigators retrospectively compared participants with and without postoperative fs by their attitude towards medication and by depression scale questionnaires.


Eligibility criteria:
inclusion criteria: * shoulder arthroscopy exclusion criteria: * active frozen shoulder
dzd8586 in patients with relapsed or refractory b-cell non-hodgkin lymphoma

Conditions: Lymphoma, Non-Hodgkin

Summary: this study will treat patients with b-nhl who have relapsed, progressed, or were intolerant to systemic therapy progressed following prior therapy. this study will help to understand what type of side effects may occur with the drug treatment. it will also measure the levels of drug in the body and assess its anti-cancer activity as monotherapy.


Eligibility criteria:
inclusion criteria: 1. male or female participants who have provided icf with age ≥ 18 yrs 2. ecog performance 0-2, no deterioration in the past 2 weeks 3. participants with relapsed or refractory b-nhl must have cytologically or histologically confirmed b-cell lymphoma 4. adequate bone marrow reserve and organ system functions 5. participants willing to comply with contraceptive restrictions exclusion criteria: 1. any unresolved \> grade 1 adverse event at the time of starting study treatment with the exception of alopecia. 2. prior history of allogeneic hematopoietic stem cell transplantation 3. stem cell transplantation, cell therapy, or gene therapy within 90 days. approved small molecule therapy within 5 half-lives, investigational small molecule therapy within 14 days. monoclonal antibodies and antibody-drug conjugates within 28 days radiation therapy within 1 weeks 4. live attenuated vaccines or viral vector vaccines within 4 weeks. major surgery or significant traumatic injury within 4 weeks. history of stroke or intracranial hemorrhage within 6 months 5. participants with non-cnsl presence of cns or intraocular lymphoma lesions. 6. cnsl participants with systemic presence of lymphoma, unable to complete lumbar puncture, under systemic corticosteroids at a dose \> 8 mg/day (dexamethasone equivalent dose) within 14 days or requiring immunosuppressive or biologic therapy." 7. participants with infectious disease: 8. clinically significant cardiac disorders or abnormalities 9. another malignancy within 5 years prior to enrollment with the exception of adequately treated in-situ carcinoma of the cervix, uterus, basal or squamous cell carcinoma or non-melanomatous skin cancer. 10. refractory nausea and vomiting if not controlled by supportive therapy, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption 11. women who are breast feeding 12. psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol
to evaluate the efficacy of oral molecular hydrogen supplement in patients with chronic diseases

Conditions: Chronic Disease; Chronic Inflammation

Summary: the supplementation of hydrogen molecules as an aid, adjuvant, may speed up recovering the course of the disease. the purpose of this study is to determine the possible efficacy and safety of solid hydrogen supplements for a clinical study in patients with chronic diseases. patients will receive hydrogen capsules with their conventional treatment for 24 weeks. investigators will test for any changes in haematologic, urine analysis and health status during and following the exposure period.

hydrogen supplement has been shown to have significant removing effects on free radicals. international clinical trials have shown promise that hydrogen molecules may reduce chronic inflammatory and then speed up recovering the course of the disease.the purpose of this study is to determine the possible efficacy and safety of hydrogen supplements in different formula and dose exposures for a clinical study in patients with chronic diseases.study design: 60 chronic diseases patients will be recruited from the taoyuan armed forces general hospital and tri-service general hospital for this study. participants will be screened by doctors for their eligibility and undergo a series of tests (questionnaires and examinations).consenting participants will then be randomly allocated into 2 groups (experiment group and control group, single-blind study). in experiment group, participants will receive 2 solid hydrogen capsules every day for 24 weeks. in control group, participants will receive 2 capsules not containing hydrogen every day for 24 weeks. participants will be examined their regular haematology, urine and health status before and after the intervention.

Eligibility criteria:
inclusion criteria: * age 20 to 80 * able to compliant with the protocol * able to return to the hospital regularly * patients with chronic inflammation, including patients with autoimmune diseases, metabolic-related diseases, chronic kidney disease or nephritis, tumor patients, etc. exclusion criteria: * pregnancy * expected pregnancy * attending other clinical trials with 6 months

Keywords: hydrogen supplement oral hydrogen capsules
exercise,metabolic syndrome and weight regain (echocardiography substudy)

Conditions: Metabolic Syndrome; Obesity

Summary: we plan to test the hypothesis that patients with metabolic syndrome will have impaired left ventricular diastolic parameters. these parameters will be measured before and after a stress test at the end of a 3 month period of exercise training and a 10% weight loss.

patients must have 2 of the 5 criteria for metabolic syndrome and be able to exercise in a monitored setting for 45 min 5 times a week.

Eligibility criteria:
inclusion criteria: * 2 of 5 criteria for metabolic syndrome * ability to exercise for 45 min 5 days a week exclusion criteria: * no diabetes * established coronary disease

Keywords: metabolic syndrome obesity exercise
impact of male provider phone calls to increase men's clinic linkage after hivst

Conditions: HIV; Linkage to Care; PMTCT; PrEP; ART Adherence

Summary: evaluate the impact of phone calls from a male counselor in increasing linkage to hiv care and prep among male partners of pregnant women attending pmtct.

evaluate the impact of phone calls from a male counselor in increasing linkage to hiv care and prep among male partners of pregnant women attending pmtct. approach: leveraging the staff and infrastructure of an ongoing study, kingasa (r01mh113434), this study will evaluate the impact of phone calls from a male counselor to encourage male partners to link to hiv care or prevention services after hiv testing. the intervention will provide male counselor follow-up to 100 male partners of pregnant women in the intervention arm of the kingasa study. exit interviews will be conducted with men and their female partners to assess acceptability and challenges associated with the intervention. outcomes assessed include art initiation among hiv-positive men and prep by hiv-negative men at 6 months. hypothesis: the intervention of a phone call from a male counselor to provide counseling and encourage linkage to hiv care or prevention will be feasible and acceptable. it will result in a higher proportion of men linking to treatment and prevention compared to the standard of care arm of the kingasa pilot study.

Eligibility criteria:
inclusion criteria for women: age ≥18 or 14-17 years if an emancipated minor (pregnant or have a child), currently pregnant, not currently enrolled in an hiv treatment study, male partner not known to be hiv-positive or has not tested in the past 3 months, able and willing to provide written informed consent, able and willing to provide adequate locator information for study retention purposes, screening negative for any indication of intimate partner violence or social harm inclusion criteria for men: female partner enrolled in kingasa pilot study.
botox for chronic pelvic pain

Conditions: Pelvic Floor Disorders

Summary: the purpose of this research study is to find out if precise, targeted injection of botulinum neurotoxin (commonly known as botox) provides better relief of pelvic floor hypertonicity and pain than the standard method being used. the researchers want to better understand the effects (good and bad) of targeted botulinum neurotoxin injections in women with pelvic floor disorders.


Eligibility criteria:
inclusion criteria: 1. females between 18 and 60 years of age 2. clinical diagnosis of interstitial cystitis/bladder pain symptoms 3. complaints of pain, pressure, or discomfort in the bladder and/or pelvic area for the past 6 months or more, associated with lower urinary tract symptoms (such as frequency of urination), in the absence of other explanation of the symptoms (e.g., uti) \* 4. myofascial pain diagnosed with palpable bands or nodules of contracted muscle fibers 5. pelvic muscle tenderness by assessment of pelvic floor muscles on digital pelvic examination 6. no botulinum neurotoxin pelvic floor muscle injection treatment within 6 months prior to recruitment 7. able to provide informed consent exclusion criteria: 1. males 2. women \ 60 years of age 3. history of pelvic malignancy and sexual transmitted diseases that is currently not in remission 4. bleeding disorder such as coagulopathy 5. hypersensitivity to botulinum neurotoxin 6. received botulinum neurotoxin pelvic floor muscle injection within 6 months prior to recruitment 7. history of neurological disorders, such as spinal cord injury, multiple sclerosis, amyotrophic lateral sclerosis or myasthenia gravis 8. pregnancy, breast feeding or planning to get pregnant within one year after the last botulinum neurotoxin injection.
study of inupadenant (eos100850) with chemotherapy as second line treatment for nonsquamous non-small cell lung cancer

Conditions: Metastatic NSCLC - Non-Small Cell Lung Cancer; Locally Advanced NSCLC - Non-Small Cell Lung Cancer

Summary: the study will first determine the optimal dose of inupadenant to be given in combination with carboplatin and pemetrexed to patients that progressed after receiving first line anti-pd(l)1 treatment for locally advanced or metastatic non-small cell lung cancer. the efficacy and safety of the combination is then compared to standard of care carboplatin and pemetrexed in the same populations.

the study is composed of two parts. part 1 follows an open-label, dose-finding design where individual cohorts are treated with various dose levels of inupadenant combined with standard of care dosing of carboplatin and pemetrexed. the recommended phase 2 dose is determined prior to initiation of part 2 which then compares inupadenant to placebo with both arms treated in combination with standard of care carboplatin and pemetrexed. participants in both parts are enrolled from two populations of patients with nonsquamous nsclc that have progressed after first line treatment as follows: non-resectable patients treated with chemoradiotherapy followed by anti-pd-(l)1 or metastatic patients treated with anti-pd-(l)1 therapy without chemotherapy. imaging, safety and pro assessments are performed during the treatment and follow-up phase as well as pharmacokinetic and other exploratory analyses.

Eligibility criteria:
inclusion criteria: * confirmed diagnosis of metastatic (stage iv) or locally advanced, unresectable (stage iii) nsclc of nonsquamous pathology * measurable disease as defined by recist v1.1 * pd-l1 expression status available at or after the time of diagnosis. all levels of expression are eligible. * existing biopsy taken within 4 years prior to entering trial or provide fresh biopsy where safe and feasible * at least 12 weeks of treatment with only 1 anti-pd-(l)1 agent (mono or with io combo) in the metastatic setting, or at least 12 weeks of anti-pd-(l)1 agent (mono or with io combo) following crt in the unresectable, stage iii setting * ecog performance status of 0 to 1. exclusion criteria: * symptomatic central nervous system (cns) metastases or leptomeningeal disease. * egfr, alk, or ros1 mutation. * autoimmune disease requiring systemic treatment or immunodeficiency requiring concurrent use of systemic immunosuppressants or corticosteroids * hepatitis b or c infection unless adequately treated with no detectable viral load; human immunodeficiency virus (hiv) unless well-controlled disease on therapy. * history of life-threatening toxicity related to prior immune therapy * uncontrolled or significant cardiovascular disease * pregnant or breast-feeding * lack of agreement to use highly effective method of contraception during treatment and for 6 months after the last administration of chemotherapy

Keywords: non-squamous nsclc second line 2l adenosine immunotherapy
anxiety, pain, and satisfaction related to first vaginal examination in women

Conditions: Anxiety; Pain; Satisfaction

Summary: the effect of gynaecological drape and specially developed gynaecological shorts on anxiety, pain and satisfaction related to first vaginal examination in women: a randomised controlled study

many women feel anxiety and pain about gynecological examination. the aim of the study was to investigate the effect of gynaecological drape and specially developed gynaecological shorts used for the first time in vaginal examination on anxiety, pain and satisfaction related to examination.

Eligibility criteria:
inclusion criteria: * literate, * 18 years of age or older, * can speak and understand turkish, * you are a woman who is having a vaginal examination for the first time * women who volunteered to participate in the study exclusion criteria: * physical or mental illness that prevents them from communicating, * vaginal examination by a health professional other than the designated gynaecologist, * those who answered the research questions incompletely and * women who want to withdraw from the study
camrelizumab combined with apatinib mesylate or camrelizumab alone for first-line treatment in subjects with programmed death ligand 1 (pd-l1) positive relapsed or advanced non-small cell lung cancer (nsclc)

Conditions: PD-L1 Positive Non-small Cell Lung Cancer

Summary: the study is being conducted to evaluate the efficacy and safety of camrelizumab (200mg,q2w) combined with apatinib(250mg qd) in subjects with pd-l1 positive relapsed or advanced non-small cell lung cancer.


Eligibility criteria:
inclusion criteria: 1. subjects who have recurrent or advanced (stage iiib-iv) non-small cell lung cancer confirmed by histology or cytology. 2. no prior systemic treatment. subjects who have received prior neo-adjuvant, adjuvant chemotherapy, or chemoradiotherapy with curative intent for non-metastatic disease must have experienced a treatment free interval of at least 6 months from randomization since the last chemotherapy cycle. 3. subjects should not have a previously detected activating epidermal growth factor receptor (efgr) mutation or anaplastic lymphoma kinase (alk) fusion oncogene. 4. subjects must have measurable disease by computed tomography (ct) or magnetic resonance imaging (mri) per recist 1.1 criteria; 5. freshly acquired samples or archived specimens within 6 months before randomization must be provided. 6. eastern cooperative oncology group (ecog) performance status of 0-1. exclusion criteria: 1. radiologically confirmed central squamous cell carcinoma. 2. untreated central nervous system metastases (such as brain or meningeal metastases). 3. pleural effusion, pericardial effusion, or ascites with clinical symptoms that need drainage 4. past or present with idiopathic pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, tissue pneumonia (eg bronchitis, occlusive vasculitis), drug-induced pneumonia, active pneumonia during ct screening, or objective evidence of severe impairment of lung function 5. subjects with an active, known or suspected autoimmune disease. patients with type i diabetes who are receiving a stable dose of insulin, hypothyroidism who only needs hormone replacement therapy, and skin diseases (such as eczema, vitiligo, or psoriasis) that do not require systemic treatment and do not have acute deterioration within 1 year before the screening period, are allowed. 6. subjects with suspected active tuberculosis should be examined for chest x-rays, sputum, and ruled out by clinical signs and symptoms. 7. uncontrolled cardiac symptoms or diseases. 8. subjects with high blood pressure who cannot be controlled well with antihypertensive drugs (systolic blood pressure ≥140 mmhg or diastolic blood pressure ≥90 mmhg). 9. arterial / venous thrombosis events, such as cerebrovascular accidents (including transient ischemic attacks, cerebral hemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary embolism, occurred within the first 6 months of randomization. 10. subjects who have previously received anti-pd-1 / pd-l1 monoclonal antibody, anti-cytotoxic t lymphocyte antigen-4 monoclonal antibody, or vascular endothelial growth factor receptor (vegfr) small molecule inhibitor therapy.